Stocks and Investing
Stocks and Investing
Fri, March 16, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, March 15, 2018
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Sumant Kulkarni Maintained (VYGR) at Strong Buy with Decreased Target to $35 on, Mar 15th, 2018
Sumant Kulkarni of Canaccord Genuity, Maintained "Voyager Therapeutics, Inc." (VYGR) at Strong Buy with Decreased Target from $36 to $35 on, Mar 15th, 2018.
Sumant has made no other calls on VYGR in the last 4 months.
There are 4 other peers that have a rating on VYGR. Out of the 4 peers that are also analyzing VYGR, 2 agree with Sumant's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- David Nierengarten of "Wedbush" Downgraded from Buy to Hold on, Monday, March 12th, 2018
- Josh Schimmer of "Evercore ISI Group" Downgraded from Buy to Hold on, Monday, March 12th, 2018
These are the ratings of the 2 analyists that currently disagree with Sumant
- Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Increased Target to $39 on, Wednesday, February 21st, 2018
- Dane Leone of "BTIG" Initiated at Strong Buy and Held Target at $32 on, Wednesday, December 20th, 2017
Contributing Sources